Prolactin Co-Staining in Acromegaly: Clinical Features and
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Objective: To compare the clinical presentation, tumor characteristics, surgical remission, and long-term biochemical control between patients with growth hormone (GH) and prolactin (PRL) co-staining pituitary adenomas (GH&PRL-PAs) and those with merely growth hormone–secreting pituitary adenomas (GH-PAs). Methods: This retrospective, single-center cohort included adults with acromegaly who underwent transsphenoidal surgery between 2000 and 2023. GH&PRL-PAs were defined by positive immunostaining for both GH and PRL. Predictors of surgical remission were assessed using multivariable logistic regression, and determinants of last-visit insulin-like growth factor 1 (IGF-1) were evaluated using multivariable linear regression. Results: Among 358 patients, 125 patients (34.9%) were classified as GH&PRL-PAs. Median follow-up was 103 [51-144] months. Women comprised 59.2% of the cohort; female sex was similarly distributed between GH&PRL-PAs and GH-PAs (54.4% vs. 61.8%, P = .174). GH&PRL-PAs had lower GH levels at diagnosis (6.3 [3.2-23] vs. 12.4 [5-29.7] ng/mL, P = .023), postoperatively (1.2 [0.3-3.9] vs. 2.2 [0.3-3.9] ng/mL, P = .021), and at the last visit (1.2 [0.5-3.3] vs. 1.4 [0.6-3.6] ng/mL, P = .006). Insulin-like growth factor 1 levels were comparable at diagnosis and the last visit. Tumor size and Ki-67 index were similar, whereas cavernous sinus invasion was less frequent in GH&PRL-PAs (39.8% vs. 53.1%, P = .027). Surgical remission neither differed significantly between groups (37.6% vs. 28.8%, P = .087) nor did active disease at the last visit (17.6% vs. 17.2%, P = .918). Prolactin staining was not an independent predictor of surgical remission or last-visit IGF-1. Conclusion: Growth hormone and prolactin co-staining pituitary adenomas show a distinct hormonal profile, but PRL co-staining alone does not appear to determine surgical or long-term biochemical outcomes. Cite this article as: Sulu C, Tanrıöver N, Sarıçoban CT, Gazioğlu N, Kadıoğlu P. Prolactin co-staining in acromegaly: clinical features and long-term outcomes. Cerrahpaşa Med J 2026, 50, 0096, doi: 10.5152/cjm.2026.26096.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Prolactin Co-Staining in Acromegaly: Clinical Features and
- Date Crossref
- 24/08/2026
- Éditeur
- AVES YAYINCILIK A.Ş.
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.